Sun Pharmaceutical gets SEZABY FDA approval for neonatal seizures

Sun Pharmaceutical gets SEZABY FDA approval for neonatal seizures

Sun Pharmaceutical Industries has secured approval for SEZABY (phenobarbital sodium powder for injection) from the US Food and Drug Administration (FDA) for the treatment of neonatal seizures. According to Sun Pharmaceutical, the approval makes SEZABY the first and only product to be indicated specifically in the US for treating neonatal seizures in term and preterm […]

Sun Pharmaceutical subsidiary acquires Alchemee business from Galderma

Sun Pharmaceutical subsidiary acquires Alchemee business from Galderma

Sun Pharmaceutical Industries said that its subsidiary Taro Pharmaceutical Industries’ fully-owned subsidiary Taro Pharmaceuticals U.S.A., has acquired Delaware-based Galderma Holdings, Japan-based Proactiv YK, Canada-based The Proactiv Company, and other assets of The Proactiv Company Sari. The consideration for the deal is $99.28 million. Galderma Holdings, which is incorporated in Delaware, Proactiv YK, The Proactiv Company, […]

Sun Pharma to settle patent litigation with Celgene for generic Revlimid

Sun Pharma to settle patent litigation with Celgene for generic Revlimid

Sun Pharmaceutical Industries (Sun Pharma) along with one of its fully-owned subsidiaries has reached an agreement with Celgene, a fully-owned subsidiary of Bristol Myers Squibb, to resolve the patent litigation pertaining to generic Revlimid (lenalidomide). The patent litigation is about the submission of an abbreviated new drug application (ANDA) for a generic version of lenalidomide […]

SPARC succeeds in phase 3 trial of PDP-716 in glaucoma patients

SPARC succeeds in phase 3 trial of PDP-716 in glaucoma patients

Sun Pharma Advanced Research Company (SPARC) has succeeded in a phase 3 clinical trial for PDP-716 ophthalmic suspension, its investigational drug for the treatment of open angle glaucoma or ocular hypertension. The late-stage clinical trial met its pre-specified primary endpoint by showing that daily once dosing of PDP-716 is equivalent to Alphagan P 0.1% dosed […]

Sun Pharma signs licensing deal with Lilly for Covid-19 drug baricitinib

Sun Pharma signs licensing deal with Lilly for Covid-19 drug baricitinib

Sun Pharmaceutical Industries (Sun Pharma) said that it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for expanding access to the latter’s baricitinib in India. The Indian pharma company Sun Pharma will manufacture and distribute baricitinib in India. Baricitinib has been granted restricted emergency use by India’s Central Drugs Standard […]

Sun Pharma collaborates with ICGEB to develop affordable dengue vaccine

Sun Pharma collaborates with ICGEB to develop affordable dengue vaccine

Sun Pharma, an Indian multinational pharmaceutical company, has announced a collaboration with the International Centre for Genetic Engineering and Biotechnology (ICGEB) to develop a new dengue vaccine aimed at being safer, more effective, and more affordable than existing vaccines. This initiative marks the second collaboration between Sun Pharma and ICGEB, building on their earlier partnership […]